Dyne Therapeutics, Inc. $DYN Shares Sold by Squarepoint Ops LLC

Squarepoint Ops LLC lowered its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 64.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 300,074 shares of the company’s stock after selling 534,102 shares during the period. Squarepoint Ops LLC owned approximately 0.16% of Dyne Therapeutics worth $6,665,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in DYN. Nykredit A S purchased a new stake in shares of Dyne Therapeutics during the 2nd quarter valued at $113,000. California State Teachers Retirement System raised its position in shares of Dyne Therapeutics by 2,049.2% in the 2nd quarter. California State Teachers Retirement System now owns 3,001,615 shares of the company’s stock worth $66,666,000 after buying an additional 2,861,952 shares during the period. Moore Capital Management LP boosted its holdings in Dyne Therapeutics by 288.2% in the second quarter. Moore Capital Management LP now owns 305,794 shares of the company’s stock valued at $6,792,000 after acquiring an additional 227,029 shares during the last quarter. Two Sigma Securities LLC acquired a new position in Dyne Therapeutics in the second quarter valued at $222,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Dyne Therapeutics during the second quarter valued at about $5,448,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

More Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Morgan Stanley reaffirmed its Buy rating on Dyne, signaling continued confidence in the company’s pipeline and long-term outlook. Morgan Stanley reaffirmed Buy rating
• Positive Sentiment: RBC maintained an Outperform rating, saying Dyne’s DM1 approach remains differentiated, although it reduced its price target from $35 to $30. Investors are also awaiting additional six- and 12-month data for DYNE-101 and topline results from the fully enrolled ACHIEVE expansion cohort, expected in the first quarter of 2027. RBC assessment of Dyne’s DM1 approach
• Neutral Sentiment: Unusually heavy call-option activity was reported, with roughly 20,532 calls traded versus average daily volume of about 464. The activity may indicate speculative expectations for a rebound or clinical-data catalyst, but it does not establish improving fundamentals. Unusually large options trading in DYN
• Neutral Sentiment: Reported short interest was zero shares, implying no meaningful short-selling position or days-to-cover exposure based on the figures provided. This is unlikely to be a major near-term trading catalyst.
• Negative Sentiment: JPMorgan downgraded DYN from Neutral to Underweight and cut its price target from $17 to $10. The move followed a rival DM1 therapy’s Phase 3 failure, which raised concerns about clinical and commercial risks across the disease class. JPMorgan downgrade following Novartis setback
• Negative Sentiment: An insider sold 900 shares for approximately $21,915, reportedly to cover tax withholding tied to vested equity awards. The sale was small relative to the insider’s remaining holdings, limiting its fundamental significance, but it may add modestly to cautious sentiment. Dyne insider stock sale

Analysts Set New Price Targets

DYN has been the subject of several research analyst reports. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a research note on Thursday, July 23rd. They set an “overweight” rating for the company. Royal Bank Of Canada decreased their target price on Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday. Morgan Stanley dropped their target price on shares of Dyne Therapeutics from $45.00 to $36.00 and set an “overweight” rating for the company in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Dyne Therapeutics in a report on Monday, August 17th. Finally, JPMorgan Chase & Co. cut shares of Dyne Therapeutics from a “neutral” rating to an “underweight” rating and reduced their price target for the company from $17.00 to $10.00 in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $32.17.

Insider Buying and Selling

In related news, insider Douglas Kerr sold 3,745 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $24.35, for a total transaction of $91,190.75. Following the transaction, the insider directly owned 163,854 shares of the company’s stock, valued at approximately $3,989,844.90. The trade was a 2.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Erick Lucera sold 2,362 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the transaction, the chief financial officer owned 121,563 shares of the company’s stock, valued at approximately $2,476,238.31. This represents a 1.91% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 4,150,974 shares of company stock valued at $99,697,629. Corporate insiders own 9.46% of the company’s stock.

Dyne Therapeutics Stock Down 4.0%

Shares of NASDAQ DYN opened at $18.42 on Friday. The stock has a fifty day moving average price of $24.68 and a 200 day moving average price of $20.54. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a 12-month low of $11.92 and a 12-month high of $27.31. The company has a market cap of $3.44 billion, a P/E ratio of -5.53 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Research analysts anticipate that Dyne Therapeutics, Inc. will post -3.51 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.